B07 | LONG-TERM CLINICAL OUTCOMES WITH TISAGENLECLEUCEL IN HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: 4-YEAR FOLLOW-UP FROM THE PHASE 2 ELARA STUDY

Background: Treatment approach for relapsed/refractory follicular lymphoma (r/r FL) depends on previous treatments and patients’ characteristics. Tisagenlecleucel is a Chimeric Antigen Receptor T-cell therapy (CAR-T) approved for adults with r/r FL after at least two prior lines of systemic therapy...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	P.L. Zinzani, C. Thieblemont, M. Dreyling, M.J. Dickinson, J. Martínez-Lopez, A. Kolstad, J. Butler, M. Ghosh, L.L. Popplewell, J.C. Chavez, E. Bachy, K. Kato, H. Harigae, M.J. Kersten, C. Andreadis, P.A. Riedell, P.J. Ho, J.A. Pérez-Simón, A. Chen, L. Nastoupil, B. Von Tresckow, A.J.M. Ferreri, T. Teshima, P.E.M. Patten, J.P. Mcguirk, F. Offner, A. Viardot, R. Malladi, A. Zia, R. Awasthi, D. Germano, R.J. Ramos, P. Hsu, S.J. Schuster, N.H. Fowler
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Ferrata Storti Foundation 2025-09-01
Rangatū:	Haematologica
Urunga tuihono:	https://haematologica.org/article/view/12859
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!